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Available online 5 March 2016A 68 years oldmale patientwith history of dyslipidemia and smokingwas admitted to our emergency department
with complaint of dyspnea. He was transferred to the coronary care unit with the pre-diagnosis of acute coronary
syndrome. In his transthoracic echocardiography, we detected anterior, anterior septal and apical wall akinesia
with an LV ejection fraction (EF) of 25%, moderate mitral regurgitation and 13 × 6 mm sized thrombus in the
LV. Apixaban treatment 5 mg po bid was started. In the second month transthoracic echocardiograpy, the
thrombus in LV was found to have disappeared. In this report we present a patient whose LV thrombus was
successfully treated after myocardial infarction by apixaban.
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Left ventricular thrombus is usually seen in situations with reduced
left ventricular (LV) function including dilated cardiomyopathy and LV
aneurysms or aftermyocardial infarction (MI).1 In observational studies
and meta-analyses, anticoagulant therapy is recommended in order to
minimize embolization risk.2,3 An oral vitamin K antagonist, warfarin,
has been being used as an anticoagulant for this purpose for a long pe-
riod of time. New oral anticoagulants (NOACs: dabigatran, rivaroxaban,
apixaban, etc.) were found to be non-inferior or superior compared to
warfarin in prevention of thromboembolism in patients with non-
valvular atrial ﬁbrillation.2 Nevertheless, the data about the role of
new oral anticoagulants in themanagement of LV thrombus is deﬁcient.
Case report
A 68 years old male patient with history of dyslipidemia and
smoking was admitted to our emergency department with complaint
of dyspnea. The ECG was in sinus rhythm and there were precordial T
wave negativity. In his initial evaluation, the consecutive two troponin
levels were greater than the upper reference limit. After then he was
transferred to the coronary care unit with the pre-diagnosis of acute
coronary syndrome. In his transthoracic echocardiography, we detected
anterior, anterior septal and apical wall akinesia with an LV ejection, Erzurum Region Training and




y. Production and hosting by Elsevfraction (EF) of 25%, moderate mitral regurgitation and 13 × 6 mm
sized thrombus in the LV (Fig. 1). The thrombus was detected to be
mobile and attached to the distal portion of the anterior septum. The
D-dimer level was greater than the upper reference level. In coronary
angiography, left anterior descending artery was found to be totally oc-
cluded in its ostium. In positron emission tomography, the anteriorwall
was detected to be non-viable. As a result, the patientwas decided to be
managed medically. Aspirine 100 mg po qd, clopidogrel 75 mg po qd
and warfarin 5 mg po qd were prescribed and then he was discharged.
The patient did not come for early outpatient visit for measurement of
international normalized ratio (INR). After 30 days of discharge, he
was admitted to our outpatient clinic with gastrointestinal (GI) bleed-
ing. In his laboratory examination, he was found to have an INR of 10.
Then, he was hospitalized and the warfarin was stopped. Both upper
and lower GI endoscopy were performed by gastroenterology clinic
and there was not any active bleeding points in the gut. The bleeding
was considered to be due to warfarin overdose. During follow up, the
patient was hemodynamically stable. In the control transthoracic
echocardiograpy, the thrombus was found to be persisted with its pre-
viously measured dimensions. His body weight and creatinine level
were in suitable range for apixaban treatment (weight:72 kg and
creatinine:0,9 mg/dl). Since the patient was non-compliant and could
not tolerate warfarin therapy, apixaban 5 mg po bid was started. In
the second month transthoracic echocardiograpy, the thrombus in LV
was found to be disappeared (Fig. 2).
Discussion
In this report we present a patient whose LV thrombus was success-
fully treated after myocardial infarction by apixaban. LV thrombus after
MI is related to worse prognosis and increased thromboembolic risk.3ier B.V. All rights reserved. This is an open access article under the CC BY-NC-ND license
Fig. 1. Two dimensional echocardiogram shows left ventricular apical thrombus (13 × 6 mm).
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therapy) increases bleeding risk substantially.4 As a result, time of initi-
ation and duration of triple antithrombotic therapy should be adjusted
according to the atherothrombotic, cardioembolic and bleeding risk of
the patients. Our patient had triple therapy for one month because of
high bleeding risk (HAS-BLED score greater than 2).4 After one month,
clopidogrel has stopped and we have continued with aspirin and
apixaban. LV thrombus resolution with warfarin therapy was demon-
strated in some previous observational studies and meta-analyses.3,5
The role of new oral anticoagulants in reducing thrombo-embolic risk
in patients with LV mural thrombus is needed to be clariﬁed. The slow
onset of action, need for dose adjustments and regular monitoring to
provide adherence to the narrow therapeutic range, dietary restrictions,
and multiple drug interactions limit the use of vitamin K antagonists.6
NOACs do not have these kind of limitations and may also reduce the
risk of hemorrhagic stroke.6 In the ARISTOTLE trial, apixaban was
shown to have superior efﬁcacy in reducing stroke, systemic embolism,
and all cause mortality compared to warfarin.7 In 2014 American Heart
Association stroke guidelines, NOACs are recommended for three
months in patients with LV mural thrombus intolerant to warfarin
with a new class 2b recommendation and a level of evidence C.8 We
stopped warfarin and started apixaban in our patient because of highly
increased supratherapeutic INR and gastrointestinal bleeding. In the
second month of therapy, LV thrombus was found to be completely
resolved.Fig. 2.Apicalmural thrombus resolved completely after 8weeks treatmentwith apixaban.There are several limitations of the use of NOACs. The careful use in
elderly and patients with renal impairment is recommended.9 The data
is scant regarding the use of NOACs in pregnant women, pediatric
patients and the patients with valvular disease.9 Except dabigatran,
the absence of approved antidotes in the case of life-threatening hemor-
rhage or surgery is another limitation for their use.9
In conclusion; our case showed that LV thrombus can be successfully
treated by apixaban. However, randomized clinical trials are needed in
order to elucidate and conﬁrm the use of NOACs as an alternative to
warfarin.
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